Antithrombotic Strategies Targeting Thrombin Activities, Thrombin Receptors and Thrombin Generation

• References

• 1 Morrissey JH, Fakhrai H, Edgington TS. Molecular cloning of the cDNA for tissue factor, the cellular receptor for the initiation of the coagulation protease cascade. Cell 1987; 50: 129-135
• 2 Krishnaswamy S, Field KA, Edgington TS, Morrissey JH, Mann KG. Role of the membrane surface in the activation of human coagulation factor X. J Biol Chem 1992; 267: 26110-26120
• 3 Furie B, Furie BC. Molecular and cellular biology of blood coagulation. N Engl J Med 1992; 326: 800-806
• 4 Mutucumarana VP, Duffy EJ, Lollar P, Johnson AE. The active site of factor IXa is located far above the membrane surface and its conformation is altered upon association with factor VIIIa: a fluorescence study. J Biol Chem 1992; 267: 17012-17021
• 5 Ross R. The pathogenesis of atherosclerosis: a perspective for the 1990’s. Nature 1993; 362: 801-809
• 6 Rosenberg RD. Vascular smooth muscle cell proliferation: basic investigations and new therapeutic approaches (review). Thromb Haemost 1993; 70: 10-16
• 7 Fager G. Thrombin and proliferation of vascular smooth muscle cells (review). Circ Res 1995; 77: 645-650
• 8 Harker LA, Maraganore JM, Hirsh J. Novel antithrombotic agents. In: Colman RW, Hirsh J, Marder VJ, Salzman EW. editors. Hemostasis and Thrombosis: Basic Principles and Clinical Practice. 3rd . ed. Philadelphia: J.P. Lippincott; 1994: 1638-1660
• 9 Weitz JI, Hudoba M, Massel D, Maraganore J, Hirsh J. Clot-bound thrombin is protected from inhibition by heparin-anti-thrombin III but is susceptible to inactivation by antithrombin III-independent inhibitors. J Clin Invest 1990; 86: 385-391
• 10 Lumsden AB, Kelly AB, Schneider PA, Krupski WC, Dodson T, Hanson SR, Harker LA. Lasting safe interruption of endarterectomy thrombosis by transiently infused antithrombin peptide D-Phe-Pro-ArgCH2C1 in baboons. Blood 1993; 81: 1762-1770
• 11 Kelly AB, Marzec UM, Krupski W, Bass A, Cadroy Y, Hanson SR, Harker LA. Hirudin interruption of heparin-resistant arterial thrombus formation in baboons. Blood 1991; 77: 1006-1012
• 12 Eriksson BI, Kalebo P, Eckman S. Direct thrombin inhibition with rec-hirudin (CGP 39393) as prophylaxis of thromboembolic complications after total hip replacement. Thromb Haemost 1994; 72: 227-231
• 13 Eriksson BI, Kalebo P, Ekman S. Effective prevention of thromboembolic complications after total hip replacement with three different doses of recombinant hirudin. CGP 39393 (Revasc), compared to unfractionated heparin. Circulation 1994; 90: 001-569
• 14 Eriksson BI, Ekman S, Kalebo P, Zachrisson B, Bach D, Close P. Prevention of deep-vein thrombosis after total hip replacement: direct thrombin inhibition with recombinant hirudin, CGP 39393. Lancet 1996; 347: 635-639
• 15 Ginsberg JS, Nurmohamed MT, Gent M, MacKinnon B, Sicurella J, Brill-Edwards P, Levine MN, Panju AA, Powers P, Stevens P, Turpie AGG, Weitz J, Buller HR, Ten CateJW, Neemeh J, Adelman B, Fox I, Maraganore J, Hirsh J. Use of hirulog in the prevention of venous thrombosis after major hip or knee surgery. Circulation 1994; 90: 2385-2389
• 16 Agnelli G, Pascucci C, Cosmi B, Nenci GG. The comparative effects of recombinant hirudin (CGP 39393) and standard heparin on thrombus growth in rabbits. Thromb Haemost 1990; 63: 204-207
• 17 Scharfstein JS, Abendschein DR, Eisenberg PR, George D, Cannon CP, Becker RC, Sobel B, Cupples LA, Braunwald E, Loscalzo J. Usefulness of fibrinogenolytic and procoagulant markers during thrombolytic therapy in predicting clinical outcomes in acute myocardial infarction. TIMI-5 investigators (Thrombolysis in Myocardial Infarction). Am J Cardiol 1996; 78: 503-510
• 18 Lidon R-M, Theroux P, Lesperance J, Adelman B, Bonan R, Duval D, Levesque J. A pilot, early angiographic patency study using a direct thrombin inhibitor as adjunctive therapy to streptokinase in acute myocardial infarction. Circulation 1994; 89: 1567-1572
• 19 Theroux P, Perez-Villa F, Waters D, Lesperance J, Shabani F, Bonan R. Randomized double-blind comparison of two doses of hirulog with heparin as adjunctive therapy to streptokinase to promote early patency of the infarct-related artery in acute myocardial infarction. Circulation 1995; 91: 2132-2139
• 20 White HD, Aylward PE, Frey JJ, Adgey AAJ, Nair R, Hillis WS, Shalev Y, Brown MA, French JK, Collins R, Maraganore J, Adelman B. Hirulog Early Reperfusion/Occlusion (HERO) Trial Investigators. A randomized, double-blind comparison of hirulog versus heparin in patients receiving streptokinase and aspirin for acute myocardial infarction (HERO). Circulation. 1997 In press
• 21 Antman EM. TIMI 9A Investigators. Hirudin in acute myocardial infarction: Safety report from the Thrombolysis and Thrombin Inhibition in Myocardial Infarction (TIMI) 9A Trial. Circulation 1994; 90: 1624-1630
• 22 Antman EM. Hirudin in acute myocardial infarction. Thrombolysis and Thrombin Inhibition in Myocardial Infarction (TIMI) 9B trial. Circulation 1996; 94: 911-921
• 23 Klement P, Borm A, Hirsh J, Maraganore J, Wilson G, Weitz J. The effect of thrombin inhibitors on tissue plasminogen activator induced thrombolysis in a rat model. Thromb Haemost 1992; 68: 64-68
• 24 Knabb RM, Kettner CA, Reilly TM. Thrombin inhibition with DuP 714 accelerates reperfusion and delays reocclusion in dogs. Circulation 1991; 84 (Suppl. 02) 002-467 Abstract
• 25 Topol EJ, Bonan R, Jewitt D, Sigwart U, Kakkar VV, Rothman M, deBono D, Ferguson J, Willerson JT, Strony J, Ganz P, Cohen MD, Raymond R, Fox I, Maraganore J, Adelman B. Use of a direct antithrombin, Hirulog, in place of heparin during coronary angioplasty. Circulation 1993; 87: 1622-1629
• 26 Bittl JA. Comparative safety profiles of hirulog and heparin in patients undergoing coronary angioplasty. The Hirulog Angioplasty Study Investigators. Am Heart J 1995; 130: 658-665
• 27 van den BossAA, Deckers JW, Heyndrickx GR, Laarman GJ, Suryapranata H, Zijlstra F, Close P, Rojnierse JJ, Buller HR, Serruys PW. Safety and efficacy of recombinant hirudin (CGP 39 393) versus heparin in patients with stable angina undergoing coronary angiplasty. Circulation 1993; 88: 2058-2066
• 28 Zoldhelyi P, Webster MWI, Fuster V, Grill DE, Gaspar D, Edwards SJ, Cabot CF, Chesebro JH. Recombinant hirudin in patients with chronic, stable coronary artery disease: Safety, halflife, and effect on coagulation parameters. Circulation 1993; 88: 2015-2022
• 29 GUSTO IIa Investigators. Randomized trial of intravenous heparin versus recombinant hirudin for acute coronary syndromes. Circulation. 1994 60. 1631-1637
• 30 Cannon CP, Maraganore JM, Loscalzo J, McAllister A, Eddings K, George D, Selwyn AP, Adelman B, Fox I, Braunwald E. Anticoagulant effects of hirulog, a novel thrombin inhibitor, in patients with coronary artery disease. Am J Cardiol 1993; 71: 778-782
• 31 Bittl JA, Strony J, Brinker JA, Ahmed WH, Meckel CR, Chaitman BR, Maraganore J, Deutsch E, Adelman B. Treatment with bivalirudin (Hirulog) as compared with heparin during coronary angioplasty for unstable or postinfarction angina. Hirulog Angioplasty Study Investigators. N Engl J Med 1995; 333: 764-769
• 32 Fuchs J, Cannon CP. Hirulog in the treatment of unstable angina: results of the Thrombin Inhibition in Myocardial Ischemia (TIMI) 7 Trial. Circulation 1995; 92: 727-733
• 33 Harker LA, Hanson SR, Kelly AB. Antithrombotic benefits and hemorrhagic risks of direct thrombin antagonists. Thromb Haemost 1995; 74: 464-472
• 34 Hanson SR, Griffin JH, Harker LA, Kelly AB, Esmon CT, Gruber A. Antithromboticeffects of thrombin-induced activation of endogenous protein C in primates. J Clin Invest 1993; 92: 2003-2012
• 35 Gruber A, Hanson SR, Kelly AB, Yan BS, Bang N, Griffin JH, Harker LA. Inhibition of thrombus formation by activated recombinant protein C in a primate model of arterial thrombosis. Circulation 1990; 82: 578-585
• 36 Wu QY, Sheehan JP, Tsiang M, Lentz SR, Birktoft JJ, Sadler JE. Single amino acid substitutions dissociate fibrinogen-clotting and thrombomodulin-binding activities of human thrombin. Proc Natl Acad Sci USA 1991; 88: 6775-6779
• 37 Gibbs CS, Coutre SE, Tsiang M, Li W-X, Jain AK, Dunn KE, Law VS, Mao CT, Matsumura SY, Mejza SJ, Paborsky LR, Leung LLK. Conversion of thrombin into an anticoagulant by protein engineering. Nature 1995; 378: 413-416
• 38 Tsiang M, Paborsky LR, Li W-X, Jain AK, Mao CT, Dunn KE, Lee DW, Matsumura SY, Matteucci MD, Coutre SE, Leung LLK, Gibbs CS. Protein engineering thrombin for optimal specificity and potency of anticoagulant activity in vivo. Biochemistry. 1997 In press
• 39 Maruyama I, Saito H, Matsuda T, Aoki N. Antithrombotic effect of recombinant soluble human thrombomodulin on disseminated intravascular coagulation. Zimmerman Conf Proc 1996; 01: 82 Abstract
• 40 Coughlin SR, Vu T-KH, Hung DT, Wheaton VI. Characterization of a functional thrombin receptor. Issues and opportunities. J Clin Invest 1992; 89: 351-355
• 41 Connolly AJ, Ishihara H, Kahn ML, Farese Jr. RV, Coughlin SR. Role of the thrombin receptor in development and evidence for a second receptor. Nature 1996; 381: 516-519
• 42 Ishihara H, Connolly AJ, Zeng D, Kahn ML, Zheng YW, Timmons C, Tram T, Coughlin SR. Protease-activated receptor 3 is a second thrombin receptor in humans. Nature 1997; 386: 502-506
• 43 Santulli RJ, Derian CK, Darrow AL, Tomko KA, Eckardt AJ, Seiberg M, Scarborough RM, Andrade SP. Evidence for the presence of a protease-activated receptor distinct from the thrombin receptor in human keratinocytes. Proc Natl Acad Sci USA 1995; 92: 9151-9155
• 44 Cook JJ, Sitko GR, Bednar B, Condra C, Mellott MJ, Feng DM, Nutt RF, Shafer JA, Gould RJ, Connolly TM. An antibody against the exosite of the cloned thrombin receptor inhibits experimental arterial thrombosis in the African green monkey. Circulation 1995; 91: 2961-2971
• 45 Harker LA, Lundell A, Dichek DA, Rade JJ, Anderson J, Kelly AB, Hanson SR. Reduction in vascular lesion formaton (VLF) by hirudin secreted from retroviral-transduced confluent endothelial cells on vascular grafts in baboons. Thromb Haemost. 1997. 77. Abstract
• 46 Harker LA, Lumsden A, Marzec U, Hughes J, Kelly A, Lobb R, Pepinsky R, Chen C, Huber A, Hanson S. Reduction in neointimal vascular lesion formation by antibody inhibition of leukocyte a₄integrin after carotid endarterectomy in non-human primates. Blood 1996; 88: 140a Abstract
• 47 Waxman L, Smith DE, Arcuri KE, Vlasuk GP. Tick anticoagulant peptide (TAP) is a novel inhibitor of blood coagulation factor Xa. Science 1990; 248: 593-596
• 48 Nutt EM, Jain D, Lenny AB, Schaffer L, Siegl PK, Dunwiddie CT. Purification and characterization of recombinant antistasin: A leech-derived inhibitor of coagulation factor Xa. Arch Biochem Biophys 1991; 285: 37-44
• 49 Beimond BJ, Friederich PW, Levi M, Vlasuk GP, Buller HR, Ten Cate JW. Comparison of sustained antithrombotic effects of inhibitors of thrombin and factor Xa in experimental thrombosis. Circulation 1996; 93: 153-160
• 50 Yokoyama T, Kelly AB, Marzec UM, Hanson SR, Kunitada S, Harker LA. Antithrombotic effects of orally active synthetic antagonist of activated factor X in nonhuman primates. Circulation 1995; 92: 485-491
• 51 Girard TJ, MacPhail LA, Likert KM, Novotny WF, Miletich JP, Broze GJ. Inhibition of factor VIIa-tissue factor coagulation activity by a hybrid protein. Science 1990; 248: 1421-1424
• 52 Haskel EJ, Torr SR, Day KC, Palmier MO, Wun T-C, Sobel BE, Abendschein DR. Prevention of arterial reocclusion after thrombolysis with recombinant lipoprotein-associated coagulation inhibitor. Circulation 1991; 84: 821-827
• 53 Jang Y, Guzman LA, Lincoff AM, Gottsauner-Wolf M, Forudi F, Hart CE, Courtman DW, Ezban M, Ellis SG, Topol EJ. Influence of blockade at specific levels of the coagulation cascade on restenosis in a rabbit ahterosclerotic femoral artery injury model. Circulation 1995; 92: 3041-3050
• 54 Maki SL, Ruf W, Huang S, Kelly C, Vlasuk GP. Nematode anti-coagulant protein C2 (C2): a potent inhibitor of factor VIIa/tissue factor complex (FVIIa/TF) requires an exosite on factor Xa (FXa) that overlaps a factor Va (FVa) binding site. Circulation 1996; 94 (Suppl. 01) 001-694 Abstract
• 55 Rote WE, Oldeschulte GL, Dempsey EM, Vlasuk GP. Evaluation of a novel small protein inhibitor of the blood coagulation factor VIIa/tissue factor complex in animal models of arterial and venous thrombosis. Circulation 1996; 94 (Suppl. 01) 001-695 Abstract